A61K 2239/56
Kidney
A61K2239/56 (Kidney) appears on 66 US grants and 129 published applications in this corpus.
Search patents in A61K- Granted patents
- 66
- Published applications
- 129
- Assignees
- 68
- Inventors
- 227
- Latest grant
- 1 Sep 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 0 | 0 |
| 1996 | 0 | 0 |
| 1997 | 0 | 0 |
| 1998 | 1 | 0 |
| 1999 | 0 | 0 |
| 2000 | 0 | 0 |
| 2001 | 0 | 0 |
| 2002 | 2 | 4 |
| 2003 | 0 | 2 |
| 2004 | 0 | 0 |
| 2005 | 0 | 4 |
| 2006 | 0 | 4 |
| 2007 | 0 | 1 |
| 2008 | 0 | 1 |
| 2009 | 1 | 5 |
| 2010 | 3 | 4 |
| 2011 | 1 | 5 |
| 2012 | 2 | 1 |
| 2013 | 2 | 4 |
| 2014 | 2 | 2 |
| 2015 | 0 | 2 |
| 2016 | 3 | 3 |
| 2017 | 2 | 7 |
| 2018 | 4 | 8 |
| 2019 | 2 | 8 |
| 2020 | 7 | 6 |
| 2021 | 9 | 12 |
| 2022 | 6 | 13 |
| 2023 | 5 | 13 |
| 2024 | 6 | 7 |
| 2025 | 4 | 8 |
| 2026 | 3 | 5 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Antigen-binding protein targeting CD70 and use thereof1 Sep 2026US 12,721,893 B2
- Chimeric antigen receptor factories and methods of use thereof17 Mar 2026US 12,577,311 B2Dana-Farber Cancer Institute, Inc.
- Genetically engineered T cells with PTPN2 knockout have improved functionality and anti-tumor activity17 Feb 2026US 12,553,030 B2Crispr Therapeutics AG
- 3-substituted piperidine compounds for Cbl-b inhibition, and use thereof2 Dec 2025US 12,485,144 B2Nurix Therapeutics, Inc.
- Chimeric antigen receptor constructs and their use in CAR-T cells25 Nov 2025US 12,479,890 B2The University of North Carolina at Chapel Hill
- Cd70-targeted cars and engineered cells comprising same and related methods25 Jun 2026US 2026/0174853 A1Juno Therapeutics, Inc.
- Immune cell engineered with il-8 receptor and use thereof7 May 2026US 2026/0124301 A1Children's National Medical Center
- Processes for generating til products using pd-1/tigit talen double knockdown5 Mar 2026US 2026/0061052 A1Cellectis
- Genetically engineered immune cells with chimeric receptor polypeptides in combination with multiple trans metabolism molecules and therapeutic uses thereof26 Feb 2026US 2026/0053924 A1
- Deriving natural killer cells from human induced pluripotent stem cells without feeder cells26 Feb 2026US 2026/0055371 A1The Florida State University Research Foundation, Inc.
Most cited
By later US patents
- In situ immunization53US 7,763,243 B2Roger Williams Medical Center · 2010
- Compositions and methods for treatment of tumors and metastatic diseases44US 6,406,689 B12002
- Ex vivo activation of immune cells42US 5,766,920 ACellcor, Inc. · 1998
- T cell receptors and related materials and methods of use42US 7,820,174 B2The United States of America as represented by the Department of Health and Human Services · 2010
- Method of treating renal cell carcinoma using activated mononuclear cells, renal tumor antigen and cimetidine24US 5,192,537 ACellcor, Inc. · 1993